10-K: China Pharma Holdings Reports Fiscal Year 2024 Results Amidst Challenging Market Conditions

Sentiment:

Annual Results 31 March 2025 4:20 PM

📋All filings for China Pharma Holdings, INC

China Pharma Holdings reports a decline in revenue for fiscal year 2024 due to increased competition and regulatory changes in the Chinese pharmaceutical market.

Worse than expectedThe company's revenue, gross profit, operating profit, and net profit all decreased compared to the previous year.

Summary

China Pharma Holdings, Inc., a Nevada holding company with operations conducted through its subsidiary Hainan Helpson Medical & Biotechnology Co., Ltd. in the PRC, reported its fiscal year 2024 results.
The company is engaged in the development, manufacture, and marketing of pharmaceutical products.
Revenue for the year ended December 31, 2024, was $4.5 million, a decrease of $2.5 million compared to $7.0 million in 2023, attributed to increased competition and regulatory changes.
The company reported a gross loss of $2.0 million for 2024, compared to a gross loss of $0.3 million in 2023.
Operating loss for 2024 was $4.59 million, compared to $2.75 million in 2023.
Net loss for 2024 was $4.74 million, compared to a net loss of $3.08 million in 2023.
The company is focusing on consistency evaluation of generic drugs and exploring the comprehensive healthcare market.
The company is also exploring Contract Manufacturing Organization (CMO) services.
The company's auditor has raised substantial doubt about its ability to continue as a going concern.
The company is taking steps to address the material weakness in its internal control over financial reporting.

Sentiment

Score: 3

Explanation: The document presents a negative outlook due to declining financial performance and concerns about the company's ability to continue as a going concern. However, the company is taking steps to address these challenges and explore new opportunities.

Positives

Helpson's Candesartan tablets passed generic-drug-consistency-evaluation in August 2023.
The company is exploring Contract Manufacturing Organization (CMO) services, generating approximately $50,000 in revenue in 2024.
The company is actively exploring the comprehensive healthcare market, launching Noni enzyme, wash-free sanitizers, and masks.
The company has sufficient production capacity for medical masks, surgical masks, KN95 masks, and N95 masks.
Helpson's N95 medical protective mask has received registration certificate at the end of 2022 and has been on the market in the mainland China nationwide.

Negatives

Revenue decreased by 35.7% from $7.0 million in 2023 to $4.5 million in 2024.
Gross loss increased from $0.3 million in 2023 to $2.0 million in 2024, with a gross loss margin of 43.8%.
Operating loss increased from $2.75 million in 2023 to $4.59 million in 2024.
Net loss increased from $3.08 million in 2023 to $4.74 million in 2024.
The company's auditor has raised substantial doubt about its ability to continue as a going concern.
The company has identified a material weakness in its internal control over financial reporting.

Risks

The company faces intense competition in the Chinese pharmaceutical market.
Regulatory changes and government policies could adversely affect the company's operations.
The company's reliance on a limited number of distributors poses a risk.
The company's ability to obtain raw materials from key suppliers on acceptable terms is uncertain.
The company's ability to manage its employees and distribution network effectively is a risk.
The company has limited insurance coverage and may incur losses from product liability claims or business interruptions.
The company's future liquidity needs are uncertain, and it may need to raise additional funds.
The company's dependence on key employees and consultants is a risk.
Power shortages, natural disasters, or other calamities could disrupt production.
The company cannot guarantee the protection of its intellectual property rights.
Adverse changes in political and economic policies of the PRC government could affect economic growth and the company's competitive position.
The Chinese government may intervene with or influence the company's business at any time.
The PRC legal system has inherent uncertainties that could limit legal protections available to the company.
The Holding Foreign Companies Accountable Act and related regulations could pose regulatory risks and restrictions.

Future Outlook

The company is focusing on consistency evaluation of generic drugs, exploring the comprehensive healthcare market, and exploring Contract Manufacturing Organization (CMO) services to drive future growth.

Management Comments

Helpson has always taken the task of promoting the consistency evaluation as a top priority, and worked on them actively.
Helpson has taken a more cautious and flexible attitude towards initiating and progressing any project for existing products consistency evaluation to cope with the changing macro environment of drug sales in China.
Helpson continues to explore the field of comprehensive healthcare.
Helpson has sufficient production capacity for medical masks, surgical masks, KN95 masks, and N95 masks, which also meets the personal needs for protection against other respiratory infectious diseases.

Industry Context

The Chinese pharmaceutical industry is heavily policy-driven, with policies like generic drug consistency evaluation and centralized volume-based procurement significantly shaping the market. The industry is characterized by numerous small-scale manufacturers, low industry concentration, and intense competition over homogeneous products. An aging population and rising healthcare demand fuel industry growth, tempered by medical insurance cost controls.

Comparison to Industry Standards

The document does not contain specific comparisons to industry standards or benchmarks.
The document does not list specific comparible companies, projects, and results.

Related Party Transactions

The Company received advances totaling $2,928 and $0 and repaid $0 and $223,013 of the advances during the years ended December 31, 2023 and 2022, respectively from its Chairperson, Chief Executive Officer and Interim Chief Financial Officer, Ms. Zhilin Li.
On July 8, 2019 the Company entered into a loan agreement to borrow cash of RMB 4,770,000 ($738,379) with its Chairperson, Chief Executive Officer and Interim Chief Financial Officer, Ms. Zhilin Li.

Stakeholder Impact

Shareholders may be concerned about the company's declining financial performance and the auditor's doubt about its ability to continue as a going concern.
Employees may be affected by potential cost-cutting measures and restructuring efforts.
Customers may be affected by changes in the company's product portfolio and distribution network.
Suppliers may be affected by changes in the company's procurement practices.

Next Steps

The company plans to enhance the sales model of advance payment and further strengthen its collection of accounts receivable.
The company is currently exploring strategic alternatives to accelerate the launch of comprehensive healthcare products.
The company will take multiple measures simultaneously in aspects such as procurement, production, human resources, and marketing to reduce operating costs.

Key Dates

Date	Description
2005-05-25	Onny acquired 100% of the ownership in Helpson.
2005-06-12	The transaction was approved by the Commercial Bureau of Hainan Province.
2005-06-21	Helpson received its business license evidencing its WFOE status.
2010-11-12	Board of Directors adopted the 2010 Long-Term Incentive Plan.
2010-12-22	Stockholders approved the 2010 Long-Term Incentive Plan.
2019-10-17	Board of Directors approved the First Amendment to the 2010 Incentive Plan.
2019-12-19	Stockholders adopted the First Amendment to the 2010 Incentive Plan.
2021-11-17	China Pharma entered into a Securities Purchase Agreement with Streeterville Capital, LLC.
2021-11-19	The transaction contemplated under the Agreement was closed.
2021-12-27	Stockholders adopted the Amendment No.2 to the Long-Term 2010 Incentive Plan.
2022-12-21	The Company entered into a new line of credit for an aggregate amount of RMB 7,300,000 with Bank of Communications.
2022-12-27	Stockholders adopted the Amended and Restated Long Term 2010 Incentive Plan.
2023-03-06	China Pharma implemented a 1-for-10 reverse stock split.
2023-04-13	China Pharma entered into an Amendment with the Investor which extended the maturity date of the Convertible Note Payable to May 19, 2024.
2023-09-25	The Company entered into a three-year revolving loan and received proceeds of RMB 10,000,000.
2023-12-17	Stockholders adopted the Amendment No.1 to the Amended and Restated Long Term 2010 Incentive Plan.
2024-03-06	The Company implemented a 1-for-5 reverse split of its common stock.
2024-05-23	The Company entered into an Amendment No. 2 to the Note by which the parties have agreed to extend the maturity date of the Note to August 19, 2025.
2024-12-12	The Company entered into that certain securities purchase agreement with an institutional investor for an at-the-market offering.
2024-12-23	The Board of Directors approved the Amendment No.2 to the Amended and Restated Long Term 2010 Incentive Plan.
2025-03-24	Date of the report.

Keywords

pharmaceuticals, China Pharma Holdings, Hainan Helpson, revenue, net loss, consistency evaluation, generic drugs, CMO, China, pharmaceutical industry

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.